期刊文献+

Drug therapy for ulcerative colitis 被引量:21

Drug therapy for ulcerative colitis
下载PDF
导出
摘要 Ulcerative colitis (UC) is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon. Drug therapy is not the only choice for UC treatment and medical management should be as a comprehensive whole.Azulfidine, Asacol, Pentasa, Dipentum, and Rowasa all contain 5-aminosalicylic acid (5-ASA), which is the topical anti-inflammatory ingredient. Pentasa is more commonly used in treating Crohn's ileitis because Pentasa capsules release more 5-ASA into the small intestine than Asacol tablets. Pentasa can also be used for treating mild to moderate UC. Rowasa enemas are safe and effective in treating ulcerative proctitis and proctosigmoiditis. The sulfafree 5-ASA agents (Asacol, Pentasa, Dipentum and Rowasa) have fewer side effects than sulfa-containing Azulfidine. In UC patients with moderate to severe disease and in patients who failed to respond to 5-ASA compounds,systemic (oral) corticosteroids should be used. Systemic corticosteroids (prednisone, prednisolone, cortisone, etc.)are potent and fast-acting drugs for treating UC, Crohn's ileitis and ileocolitis. Systemic corticosteroids are not effective in maintaining remission in patients with UC.Serious side effects can result from prolonged corticosteroid treatment. To minimize side effects, corticosteroids should be gradually reduced as soon as the disease remission is achieved. In patients with corticosteroid-dependent or unresponsive to corticosteroid treatment, surgery or immunomodulator is considered. Immunomodulators used for treating severe UC include azathioprine/6-MP,methotrexate, and cyclosporine. Integrated traditional Chinese and Western medicine is safe and effective in maintaining remission in patients with UC. Ulcerative colitis (UC) is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon.Drug therapy is not the only choice for UC treatment and medical management should be as a comprehensive whole. Azulfidine,Asacol,Pentasa,Dipentum,and Rowasa all contain 5-aminosalicylic acid (5-ASA),which is the topical anti-inflammatory ingredient.Pentasa is more commonly used in treating Crohn's ileitis because Pentasa capsules release more 5-ASA into the small intestine than Asacol tablets.Pentasa can also be used for treating mild to moderate UC.Rowasa enemas are safe and effective in treating ulcerative proctitis and proctosigmoiditis.The sulfa- free 5-ASA agents (Asacol,Pentasa,Dipentum and Rowasa) have fewer side effects than sulfa-containing Azulfidine.In UC patients with moderate to severe disease and in patients who failed to respond to 5-ASA compounds, systemic (oral) corticosteroids should be used.Systemic corticosteroids (prednisone,prednisolone,cortisone,etc.) are potent and fast-acting drugs for treating UC,Crohn's ileitis and ileocolitis.Systemic corticosteroids are not effective in maintaining remission in patients with UC. Serious side effects can result from prolonged corticosteroid treatment.To minimize side effects,corticosteroids should be gradually reduced as soon as the disease remission is achieved.In patients with corticosteroid-dependent or unresponsive to corticosteroid treatment,surgery or irnmunomodulator is considered.Irnmunomodulators used for treating severe UC include azathioprine/6-MP, methotrexate,and cyclosporine.Integrated traditional Chinese and Western medicine is safe and effective in maintaining remission in patients with UC.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第16期2311-2317,共7页 世界胃肠病学杂志(英文版)
基金 Supported by the Science Foundation of Health Bureau of Shaanxi province,No.04D26
  • 相关文献

参考文献4

二级参考文献6

  • 1Andersen PL. Amebiasis. Ugeskr Laeger 2000; 162:1537-1541.
  • 2Hansen LH, Lund C. Amebiasis-a differential diagnosis from inflammatory bowel disease. Ugeskr Laeger 1998; 160:. 5514-5515.
  • 3Bayramicli OU, Dalay R, Konuksal F, Kilic G, Akbayir N, Ovunc O. Ulseratif kolitle amebiasisin birlikteligi. Turk J Gastroenterol 1997; 8:94-96.
  • 4Süleymanlar I, Atilgan S, Ertugrul C, Isitan F. Ulseratif kolit ve intestinal amebiasis birlikteligi ve tedavide karsilasilan sorunlar.Gastroenteroloji 1996; 7:22.
  • 5Prokopowicz D, Zagorski K, Kramarz P. Amoebiasis-a problem in patients with ulcerative colitis. Wiad Lek 1994; 47:248-251.
  • 6Chan KL, Sung JY, Hsu R, Liew CT. The association of the amoebic colitis and chronic ulcerative colitis. Singapore Med J 1995; 36:303-305.

共引文献6

同被引文献105

引证文献21

二级引证文献244

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部